Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease Care

Stuart Isaacson, MD

A special episode of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments^® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

Rajesh Pahwa, MD

This special episode episode, "What Apomorphine Infusion Approval Means for Parkinson Disease Care" covers the recent approval of Supernus Pharmaceuticals' agent SPN-830, marketed as Onapgo, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson disease (PD). SPN-830, which has been available in Europe for several years, was approved based on data from the TOLEDO study (NCT02006121), a randomized, double-blind study in which treatment with the device was associated with a difference of –1.89 hours per day of OFF time for patients with PD in comparison with placebo. To gain greater insights on how this approval impacts the clinical and patient communities, NeurologyLive^® sat down with movement disorder experts Stuart Isaacson, MD, director of the Parkinson’s disease and movement disorders center of Boca Raton, and Rajesh Pahwa, MD, the Laverne and Joyce Rider professor of neurology at the University of Kansas Medical Center. The duo discussed the significance of the approval, considerations for patient selection with the treatment, as well as the studies supporting its safety and efficacy. In addition, the pair provided context on how this approval, along with other recent approvals in PD, speak to the progress the clinical and research community has made over the years.

For more of NeurologyLive's coverage of SPN-830 for Parkinson disease, head here: FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment

EPISODE BREAKDOWN

• 1:05 – Significance of SPN-830's approval and impact on PD community
• 3:10 – Considerations for treatment selection with SPN-830, conversations with families
• 5:50 – Neurology News Minute
• 7:50 – TOLEDO study, supportive efficacy and safety data for SPN-830
• 11:45 – Expanding PD treatment options and overviewing recent progress in research

Click here to subscribe to the Mind Moments^® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCES
1. Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease. News Release. Supernus. Published February 4, 2025. Accessed March 26, 2025. https://ir.supernus.com/news-releases/news-release-details/supernus-announces-fda-approval-onapgotm-apomorphine